카테고리 없음

Bu-Kyeom Kim ‘Let’s Watch’ and Eun-Kyung Jung ‘Monitoring’ for Delta Spread

김종찬안보 2021. 7. 8. 12:30
728x90

In the quarantine system that criminalizes individual quarantine of infected people, the administration of the quarantine enforcement administration said, "Let's get tired of the spread of the delta mutation," and the director of the Korea Centers for Disease Control and Prevention said "continue monitoring."

According to the Prevention and Prevention Act, false statements based on tracking the location of the infected person will be sentenced to two years in prison and compensation for damages. There is no provision of punishment for quarantine enforcers for the prevention of quarantine, which has been given full power to the administration, and for the concealment of distortion of health and security information.

On the 8th, Prime Minister Kim Bu-gyeom (Chief Headquarters Headquarters) said, “It cannot be concluded that the 4th pandemic has begun,” and “We have no choice but to monitor the situation hourly and when experts decide that it is not possible (social distancing is raised). "It seems like it could be discussed at the Sunday major script meeting, but we have to watch the progress for a few days," he told MBC.

At a regular briefing on the 7th, Lee Ki-il, 1st Supervisor of the Korean Central News Agency, said at a regular briefing on the 7th, “I think that we are entering the beginning of the fourth epidemic as the number of confirmed cases in the metropolitan area increases in the situation of the global mutant virus epidemic.” “The current level will be maintained until July or early August. I guess it will continue,” he said.

President Moon Jae-in, presiding over a quarantine meeting in the metropolitan area on the 7th, announced that he would strengthen punishment for individuals, saying, "Apply the zero tolerance principle of the enforcement of the Infectious Disease Prevention Act." "Increase the number of local epidemiological investigations and increase the number of local epidemiological investigations to quickly identify the route of infection by expanding epidemiological investigation.・Introduce public officials,” he instructed to strengthen the quarantine law.

At a briefing on the 24th of last month, Sohn Young-rae, head of the social strategy division of the Central Accident Resolving Headquarters, said, "The status of domestic epidemic control is stable."

Jeong Eun-kyung, head of the Korea Centers for Disease Control and Prevention (KCDC), said on the 24th of last month, "Although the proportion of delta-type patients in Korea is still low, the risk of inflow or transmission exists. It is necessary to do it," he said with 'preparation for risks after observation'.

Director Jung said, "Worldwide, it has been confirmed that about 11 countries have reported the mutation, and the mutation that corresponds to Delta Plus has not yet been confirmed in the mutation confirmed in Korea." "In this regard, we will continue to monitor and monitor the impact of this virus as it is necessary to analyze or monitor how this virus affects the contagiousness, severe severity, and antibody therapy and vaccine," he said. .

In a regular briefing on the 5th, Director Jeong said, "The infection reproduction index is as high as 1.2, and 2.6% of suspected patients are confirmed, so there is a high risk of spread from the quarantine index. We will carry out special management measures in the metropolitan area without any setbacks, such as inspections, all-in-one inspections for high-risk groups, and periodic preemptive inspections.”

Prime Minister Kim said at a major headquarters meeting on the 7th, "If this situation is not caught after two or three more days, we can take even the most powerful stage of the new distancing system."

On April 30, Prime Minister Kim's major script was officially revised with the policy of 'meetings of eight people, business restrictions at 12:00 p.m.' in the metropolitan area, saying, "If the number of new confirmed cases is controlled to less than 1,000, new social distancing will be applied in July." 

At that time, the number of new confirmed cases exceeded 500, and delta mutation infections began to appear. 

At the end of June, 12.3% of the confirmed cases in the metropolitan area were delta mutations, and the detection rate of delta mutations in their 20s was confirmed at 17.1%. 

On the 7th, 577 confirmed cases in Seoul and 1,000 new cases in a row were confirmed.

 

The National Institutes of Health reported on the 25th of last month about the Celltrion Reckinona cell line experiment, “Compared to the GR group (non-mutated), the neutralizing ability of the two domestic epidemic mutations (B.1.619 and B.1.620) is maintained, but the delta type ( B.1.617.2) neutralizing ability against mutations was significantly reduced.”

The Ministry of Food and Drug Safety confirmed that the cell-line-level efficacy analysis of the Celltrion treatment (Reckinona) showed a marked decrease in neutralizing ability as a result of cell line-level efficacy analysis. We are looking forward to the results of the animal test," he said, did not respond to the continuous pouring of articles such as 'breaking news' based on propaganda.

On July 5, the media continued their psychological warfare against mutations with <Celltrion, 'Reckrona' animal test to confirm the efficacy of Brazil's 'gamma' mutations> in a situation where the risk of delta is skyrocketing.

Shinpoong Pharmaceutical's stock price soared by 1,613% in one year due to a clinical trial for a treatment for malaria, but its share price plummeted from the 6th as it failed to secure statistical significance in phase 2 clinical trials.

Regarding Shinpoong Pharmaceutical’s Pyramax, when the Ministry of Food and Drug Safety approved a phase 2 clinical trial to evaluate the efficacy and safety of a treatment for coronavirus in malaria by expanding the treatment range in May last year, its market capitalization rose from 380 billion won at the beginning of last year to 10 trillion won in nine months. soared to

On February 5, the Ministry of Food and Drug Safety (MFDS) approved Celltrion lekkona in the condition of submitting the results of phase 3 clinical trials, and phase 3 is still in progress.